Pancreatic Ductal Adenocarcinoma Pipeline 2025: Key Companies, MOA, ROA, and Clinical Trials Evaluation by DelveInsight by DelveInsight

(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Pancreatic Ductal Adenocarcinoma pipeline constitutes 80+ key companies continuously working towards developing 80+ Pancreatic Ductal Adenocarcinoma treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

"Pancreatic Ductal Adenocarcinoma Pipeline Insight, 2025" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Pancreatic Ductal Adenocarcinoma Market.

The Pancreatic Ductal Adenocarcinoma Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Pancreatic Ductal Adenocarcinoma Pipeline Report: https://www.delveinsight.com/sample-request/pancreatic-ductal-adenocarcinoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
• Companies across the globe are diligently working toward developing novel Pancreatic Ductal Adenocarcinoma treatment therapies with a considerable amount of success over the years.
• Pancreatic Ductal Adenocarcinoma companies working in the treatment market are Deciphera Pharmaceuticals, Revolution Medicines, Syntrix Biosystems, Amplia Therapeutics, ZielBio, Cend Therapeutics Inc, Cardiff Oncology, Eucure Biopharma, Jiangsu Alphamab Biopharmaceuticals, and others, are developing therapies for the Pancreatic Ductal Adenocarcinoma treatment
• Emerging Pancreatic Ductal Adenocarcinoma therapies in the different phases of clinical trials are- DCC-3116, RMC-6236, SX-682, AMP 945, ZB131, CEND-1, Onvansertib, YH003, KN046, and others are expected to have a significant impact on the Pancreatic Ductal Adenocarcinoma market in the coming years.
• In January 2026, Alpha Tau Medical Ltd. (Nasdaq: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, announced the release of final results from its first-in-human pancreatic cancer study in Montreal, Canada, investigating Alpha DaRT for pancreatic ductal adenocarcinoma (PDAC). The findings have been published in two abstracts and are scheduled to be presented at the 2026 ASCO Gastrointestinal Cancers Symposium in San Francisco, taking place January 8-10, 2026.
• In May 2025, The FDA has awarded fast track designation to EBC-129 as a potential treatment for patients with pancreatic ductal adenocarcinoma. This antibody-drug conjugate (ADC) targets a tumor-specific N256-glycosylation site present on CEACAM5 and CEACAM6, proteins involved in tumor development, migration, and metastasis. The therapy's safety and tolerability are being evaluated both as a monotherapy and in combination with pembrolizumab (Keytruda) in patients with advanced solid tumors.
• In January 2025, Lisata Therapeutics, Inc. (Nasdaq: LSTA), a clinical-stage pharmaceutical company focused on developing innovative treatments for advanced solid tumors and serious diseases, along with WARPNINE Incorporated, Western Australia's first not-for-profit clinical research organization specializing in pancreatic, gastrointestinal, and rare cancers, has announced promising preliminary results from the Phase 1b/2a iLSTA trial (ACTRN12623000223639). The trial evaluates certepetide (formerly LSTA1), Lisata's proprietary investigational iRGD cyclic peptide, in combination with standard-of-care chemotherapy and immunotherapy as a first-line treatment for locally advanced, non-resectable pancreatic ductal adenocarcinoma (PDAC).
• In October 2024, Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company focused on developing targeted therapies for RAS-addicted cancers, has announced that the first patient has been dosed in RASolute 302, a Phase 3 registrational trial evaluating RMC-6236, a RAS(ON) multi-selective inhibitor, for patients with previously treated metastatic pancreatic ductal adenocarcinoma (PDAC).
• In May 2024, Hong Kong-based biopharmaceutical company Hutchmed has initiated a Phase II/III clinical trial in China to evaluate surufatinib in combination with other drugs as a first-line treatment for metastatic pancreatic ductal adenocarcinoma (PDAC). The treatment regimen includes surufatinib, camrelizumab from Jiangsu Hengrui Pharmaceuticals, nab-paclitaxel, and gemcitabine.
• In January 2024, Jacobio Pharmaceuticals' pancreatic cancer candidate, glecirasib, has demonstrated improved safety and efficacy compared to previous studies in a Phase I/II trial involving patients with pancreatic cancer and other solid tumors. The Phase I/II monotherapy global study of glecirasib reported a confirmed objective response rate (cORR) of 48% and a disease control rate (DCR) of 90%. These study results will support the submission of a new drug application (NDA) for pancreatic cancer.

Pancreatic Ductal Adenocarcinoma Overview
Pancreatic Ductal Adenocarcinoma (PDAC) is the most common type of pancreatic cancer, arising from the ductal cells of the pancreas. It is highly aggressive, often diagnosed at an advanced stage, and associated with poor prognosis. Risk factors include age, smoking, chronic pancreatitis, diabetes, and genetic predisposition. Symptoms may include abdominal pain, jaundice, weight loss, and digestive issues, but early-stage disease is frequently asymptomatic. Treatment typically involves a combination of surgery, chemotherapy, radiation, and emerging targeted or immunotherapies, though the overall survival rate remains low due to late diagnosis and rapid disease progression.

Get a Free Sample PDF Report to know more about Pancreatic Ductal Adenocarcinoma Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/pancreatic-ductal-adenocarcinoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Emerging Pancreatic Ductal Adenocarcinoma Drugs Under Different Phases of Clinical Development Include:
• DCC-3116: Deciphera Pharmaceuticals
• RMC-6236: Revolution Medicines
• SX-682: Syntrix Biosystems
• AMP 945: Amplia Therapeutics
• ZB131: ZielBio
• CEND-1: Cend Therapeutics Inc
• Onvansertib: Cardiff Oncology
• YH003: Eucure Biopharma
• KN046: Jiangsu Alphamab Biopharmaceuticals

Pancreatic Ductal Adenocarcinoma Route of Administration
Pancreatic Ductal Adenocarcinoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
• Oral
• Intravenous
• Subcutaneous

Pancreatic Ductal Adenocarcinoma Molecule Type
Pancreatic Ductal Adenocarcinoma Products have been categorized under various Molecule types, such as
• Small molecule
• Cell Therapy
• Peptides
• Polymer
• Small molecule
• Gene therapy

Pancreatic Ductal Adenocarcinoma Pipeline Therapeutics Assessment
• Pancreatic Ductal Adenocarcinoma Assessment by Product Type
• Pancreatic Ductal Adenocarcinoma By Stage and Product Type
• Pancreatic Ductal Adenocarcinoma Assessment by Route of Administration
• Pancreatic Ductal Adenocarcinoma By Stage and Route of Administration
• Pancreatic Ductal Adenocarcinoma Assessment by Molecule Type
• Pancreatic Ductal Adenocarcinoma by Stage and Molecule Type

DelveInsight's Pancreatic Ductal Adenocarcinoma Report covers around 80+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Pancreatic Ductal Adenocarcinoma product details are provided in the report. Download the Pancreatic Ductal Adenocarcinoma pipeline report to learn more about the emerging Pancreatic Ductal Adenocarcinoma therapies
https://www.delveinsight.com/sample-request/pancreatic-ductal-adenocarcinoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key companies in the Pancreatic Ductal Adenocarcinoma Therapeutics Market include:
Key companies developing therapies for Pancreatic Ductal Adenocarcinoma are - Elicio Therapeutics, Cend Therapeutics, Silenseed Ltd, Amplia Therapeutics Limited, Bristol-Myers Squibb, Revolution Medicines, Inc., Taiho Pharmaceutical, Genmab, Deciphera Pharmaceuticals LLC, NGM Biopharmaceuticals, Multitude Therapeutics, Seagen Inc., Alligator Bioscience, Cardiff Oncology, Novartis, Jiangsu Alphamab Biopharmaceuticals Co., Ltd, Cantargia AB, Nelum Corp, GC Cell Corporation, OSE Immunotherapeutics, Eucure (Beijing) Biopharma Co., Ltd, Panbela Therapeutics, Inc., Onconic Therapeutics Inc., Tarveda Therapeutics, I-Mab Biopharma Co. Ltd., Incyte Corporation, ZielBio, Inc., DrugCendR Inc., Bayer, TriSalus Life Sciences, Jacobio Pharma, BioLineRx Ltd., Purple Biotech Ltd., Biomea Fusion, Inc., Phanes Therapeutics, Qualigen Therapeutics, and others.

Pancreatic Ductal Adenocarcinoma Pipeline Analysis:
The Pancreatic Ductal Adenocarcinoma pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Pancreatic Ductal Adenocarcinoma with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Pancreatic Ductal Adenocarcinoma Treatment.
• Pancreatic Ductal Adenocarcinoma key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Pancreatic Ductal Adenocarcinoma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Pancreatic Ductal Adenocarcinoma market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Pancreatic Ductal Adenocarcinoma drugs and therapies
https://www.delveinsight.com/sample-request/pancreatic-ductal-adenocarcinoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Pancreatic Ductal Adenocarcinoma Pipeline Market Drivers
• Increasing pervasiveness of the disease, increasing demand of targeted therapy are some of the important factors that are fueling the Pancreatic Ductal Adenocarcinoma Market.

Pancreatic Ductal Adenocarcinoma Pipeline Market Barriers
• However, lack of early diagnostic markers, complicated and multifactorial nature of disease, diverse genetics and rapid metastasis and other factors are creating obstacles in the Pancreatic Ductal Adenocarcinoma Market growth.

Scope of Pancreatic Ductal Adenocarcinoma Pipeline Drug Insight
• Coverage: Global
• Key Pancreatic Ductal Adenocarcinoma Companies: Deciphera Pharmaceuticals, Revolution Medicines, Syntrix Biosystems, Amplia Therapeutics, ZielBio, Cend Therapeutics Inc, Cardiff Oncology, Eucure Biopharma, Jiangsu Alphamab Biopharmaceuticals, and others
• Key Pancreatic Ductal Adenocarcinoma Therapies: DCC-3116, RMC-6236, SX-682, AMP 945, ZB131, CEND-1, Onvansertib, YH003, KN046, and others
• Pancreatic Ductal Adenocarcinoma Therapeutic Assessment: Pancreatic Ductal Adenocarcinoma current marketed and Pancreatic Ductal Adenocarcinoma emerging therapies
• Pancreatic Ductal Adenocarcinoma Market Dynamics: Pancreatic Ductal Adenocarcinoma market drivers and Pancreatic Ductal Adenocarcinoma market barriers

Contact Us:
Gaurav Bora
gbora@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

This release was published on openPR.